SOL is an Italian multinational group operating in the production, applied research, and commercialization of technical, pure, and medicinal gases, as well as home medical care. The company serves industrial customers in sectors such as steel, metallurgy, glass, ceramics, metal fabrication, chemicals, pharmaceuticals, food and beverage, and oil, providing compressed, liquefied, and cryogenic gases along with equipment and services. In the healthcare sector, SOL supplies hospitals, research institutes, and assisted reproduction centers with medical products and integrated operational solutions, while its home care division provides therapies for chronic patients on behalf of national health systems. The group also engages in biotechnology, focusing on genomic diagnostics, molecular genetics, and bioinformatics pipelines, and produces energy from renewable sources. Founded in 1927, SOL operates globally and maintains a presence in multiple countries, serving a large base of industrial clients and patients through its subsidiaries and specialized business units.

Summarised from the company's own disclosures, fiscal year ended Dec 2024

Industry Specialty Chemicals Homepage solgroup.com
Sector Basic Materials IR page solgroup.com/it
Tags
technical gases, medical gases, home care, biotechnology, genomic diagnostics, renewable energy, industrial gases, clinical diagnostics, bioinformatics, patient care, Vivisol, Personal Genomics, Diatheva, Cryolab
Press page —

Metrics

Valuation  
Market cap € 4.736B
Market cap (USD) $ 5.311B
P/E 30.56
PEG 1.68
P/BV 4.39
P/S 2.88
P/OCF 15.92
P/FCF 49.77
Dividend yield —
Turnover / mcap —
Returns  
ROE 15.1%
ROI 14.4%
ROIC 15.8%
Profit margin 9.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 18.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 55
Quality score 25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 1.645B 1.53B 1.49B 1.143B 996.196M
Net profit 154.957M 152.704M 137.574M 93.757M 108.234M
Free cash flow 95.161M 105.677M 93.59M 69.266M 103.838M

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024
Balance sheet detail
Trade receivables (EUR) 298M 340M 431M 448M 491M
↳ YoY growth +14.1% +26.8% +4.0% +9.6%
Cash and deposits (EUR) 269M 140M 135M 206M 232M
Intangible assets (EUR) 18.6M 22.8M 26.6M 42M 50.2M
Cash flow detail
Operating cash flow (EUR) 210M 193M 215M 270M 297M
Purchases of property, plant and equipment (EUR) -106M -123M -121M -164M -202M
Purchases of intangible assets (EUR) -11.7M -9.15M -9.83M -25.4M -17.9M
Change in receivables (cash effect) (EUR) -29.4M -25.7M -106M 13.4M 49.4M
Change in inventories (cash effect) (EUR) -13.8M -1.83M -13.8M 14M 8.39M
Change in payables (cash effect) (EUR) 13.8M 13.5M 32.1M 11.2M -29.5M
Dividends paid (cash effect) (EUR) -22.4M -23.9M -24.3M -33.5M -37.8M
Interest paid (cash effect) (EUR) -7.89M -8.15M -7.74M -11.7M -18.3M
Income taxes paid (cash effect) (EUR) -29.9M -37.2M -28.7M 37.4M 61M
Operating cash flow before change in receivables (EUR) 240M 218M 321M 257M 248M
Free cash flow (OCF - PPE - intangibles) (EUR) 92.2M 60.1M 83.8M 80.3M 77.3M
Income detail
Total comprehensive income (EUR) 97M 99.6M 146M 147M 152M
Comprehensive income to owners (EUR) 92.6M 95.4M 142M 141M 145M
Reported May 30, 2023 May 30, 2023 May 30, 2023 Apr 23, 2024 Apr 23, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

28/10/2026

Acquisizione del 100% del capitale sociale della società Wentimed, fondata dal Dott. Piotr Compała, specializzata nei trattamenti domiciliari di ventilazione meccanica e cure palliative.

Il Gruppo SOL, multinazionale operante nel settore dei gas tecnici, industriali e medicinali e nel settore dell'assistenza domiciliare con il marchio "VIVISOL", annuncia di aver rafforzato la propria posizione in Polonia con l’acquisizione del 100% di Wentimed. 

Fondata nel 2014 dal Dott. Piotr Compała, che ne ha guidato la crescita favorendo un rapido e significativo sviluppo, nel 2025 Wentimed ha raggiunto un fatturato di oltre 40 milioni di PLN (oltre 9 milioni di euro) e attualmente impiega oltre 100 dipendenti interni ed esterni. Il Dott. Compała continuerà a lavorare in Wentimed a fianco di SOL per la fase di transizione.

Maggiori dettagli nel Comunicato Stampa.

tags:

share:

notizia precedente

Ottavo gruppo mondiale, sesto in Europa e maggiore operatore italiano indipendente dalle grandi multinazionali del settore, il Gruppo SOL è proiettato verso il futuro ma con salde radici nel passato.

quick links

contatti

  • Sede legale e Direzione:
    Via Borgazzi, 27 - 20900 Monza (MB) Italy

  • +39 039 23 96 1

  • [email protected]

  • P. IVA: 00771260965

Copyright © 2026 - All rights reserved - Privacy Policy

Reset filtri

Paesi

Global

Filtra per area

Global Assistenza domiciliare Biotecnologie Gas tecnici Energia

Torna indietro

Ottavo gruppo mondiale, sesto in Europa e maggiore operatore italiano indipendente dalle grandi multinazionali del settore, il Gruppo SOL è proiettato verso il futuro ma con salde radici nel passato.

quick links

contatti

  • Sede legale e Direzione:
    Via Borgazzi, 27 - 20900 Monza (MB) Italy

  • +39 039 23 96 1

  • [email protected]

  • P. IVA: 00771260965

Copyright © 2026 - All rights reserved - Privacy Policy

Prompts

SOL S.p.A. (ticker SOL), listed in Italy.

ETFs Holding SOL S.p.A.

ETF Weight in ETF Shares Market value As of
DFIS 0.05% 41,895 $ 2.949M Nov 12, 2026
AVSD 0.02% 958 $ 69.56K Nov 16, 2026
DFSI 0.02% 3,338 $ 234.938K Nov 12, 2026
DFIC 0.01% 28,387 $ 1.998M Nov 12, 2026
DFAX 0.01% 17,647 $ 1.242M Nov 12, 2026
DFAI 0.00% 11,820 $ 831.925K Nov 12, 2026
DXIV 0.00% 145 $ 10.206K Nov 12, 2026
AVDE 0.00% 2,597 $ 188.568K Nov 16, 2026